Sunovion gets FDA nod for KYNMOBI™ as Parkinson’s Disease treatment
Sunovion has announced it has received approval from the FDA for KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the treatment of
Read more
DISEASES
New Medicine may stop COVID-19 Pandemic ‘Without Vaccination’
A Chinese laboratory has been creating a new antibody medicine considered to have the potential to cease the coronavirus pandemic,
Read more
Qatar Airways Cargo flies 54 tonnes of vaccines from Brussels to Mumbai
Qatar Airways Cargo has transported a 54-tonne shipment consisting of pneumococcal and varicella vaccines from Belgium to India. The 56
Read more
AstraZeneca to advance Oxford’s COVID-19 vaccine with $1bn investment
AstraZeneca is going to expedite the development of the University of Oxford investigational COVID-19 vaccine with a $1 billion BARDA
Read more
Pfizer’s gene therapy promising for Duchenne muscular dystrophy (DMD)
Pfizer Inc. has revealed revised clinical Phase 1b results on PF-06939926, an investigational gene therapy to treat Duchenne muscular dystrophy
Read more
ACTide EDC (Electronic Data Capture) System against COVID-19
Nubilaria, a forward thinking clinical data management company, has released an important announcement for Researchers and Health Professionals in Europe
Read more
CEPI to fund Novavax COVID-19 vaccine with up to $388 Million
CEPI has increased its investment with up to $388 million for the Novavax COVID-19 (NVX‑CoV2373) vaccine development and manufacturing. Phase
Read more
FDA clears Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for GIST
Deciphera Pharmaceuticals, Inc. has revealed that QINLOCK™ (ripretinib) was formally authorised by the U.S. Food and Drug Administration (FDA) for
Read more
Moderna’s mRNA COVID-19 vaccine (mRNA-1273) fast-tracked by FDA
Moderna, Inc., (Nasdaq: MRNA) a clinical-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced on May 12, that
Read more
FDA approves Lynparza as maintenance treatment with bevacizumab for HRD-positive ovarian cancer
AstraZeneca and Merck & Co have received the FDA’s approval for Lynparza (olaparib) as 1st-line maintenance treatment with bevacizumab for
Read more